HomeCompareTSBX vs PLD

TSBX vs PLD: Dividend Comparison 2026

TSBX yields 563.38% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TSBX wins by $156397.55M in total portfolio value
10 years
TSBX
TSBX
● Live price
563.38%
Share price
$0.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$156404.05M
Annual income
$115,926,179,183.70
Full TSBX calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — TSBX vs PLD

📍 TSBX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTSBXPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TSBX + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TSBX pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TSBX
Annual income on $10K today (after 15% tax)
$47,887.32/yr
After 10yr DRIP, annual income (after tax)
$98,537,252,306.14/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, TSBX beats the other by $98,532,784,335.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TSBX + PLD for your $10,000?

TSBX: 50%PLD: 50%
100% PLD50/50100% TSBX
Portfolio after 10yr
$78205.28M
Annual income
$57,965,717,809.94/yr
Blended yield
74.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

TSBX
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Price Target
$0.50
+40.8% upside vs current
Range: $0.50 — $0.50
Altman Z
-23.2
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TSBX buys
0
PLD buys
0
No recent congressional trades found for TSBX or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTSBXPLD
Forward yield563.38%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$156404.05M$6.50M
Annual income after 10y$115,926,179,183.70$5,256,436.18
Total dividends collected$152979.84M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$0.50$136.00

Year-by-year: TSBX vs PLD ($10,000, DRIP)

YearTSBX PortfolioTSBX Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$67,038$56,338.03$11,255$555.24+$55.8KTSBX
2$424,702$352,971.06$13,062$1,018.59+$411.6KTSBX
3$2,544,295$2,089,864.53$15,903$1,926.67+$2.53MTSBX
4$14,423,258$11,700,861.61$20,839$3,823.32+$14.40MTSBX
5$77,424,065$61,991,178.81$30,464$8,166.08+$77.39MTSBX
6$393,842,555$310,998,805.50$52,054$19,457.30+$393.79MTSBX
7$1,899,912,512$1,478,500,978.24$109,886$54,188.93+$1899.80MTSBX
8$8,698,653,014$6,665,746,626.53$304,030$186,451.18+$8698.35MTSBX
9$37,829,785,494$28,522,226,769.44$1,166,125$840,813.32+$37828.62MTSBX
10$156,404,049,663$115,926,179,183.70$6,504,190$5,256,436.18+$156397.55MTSBX

TSBX vs PLD: Complete Analysis 2026

TSBXStock

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Full TSBX Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this TSBX vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TSBX vs SCHDTSBX vs JEPITSBX vs OTSBX vs KOTSBX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.